经皮左锁骨下药盒肝动脉灌注拓僖为主治疗晚期肝癌临床分析

Injection of touxi( HCPT) through percutaneous left subclavian artery port-catheter system implantation (PSPI) for treatment of advanced primary hepatic carcinoma

目的 观察经皮左锁骨下药盒肝动脉灌注拓僖为主治疗晚期原发性肝癌的近期疗效。方法 晚期原发性肝癌82例随机分两组:A组(一次性插管组)40例,每月一次插管介入化疗栓塞治疗;B组(药盒系统组)42例,经左锁骨下动脉植入药盒系统,栓塞治疗后连续灌注拓僖5 d,6 mg/(m2·d)。结果 A组PR 19例(47.5％),Nc 18例(45.0％),PD 3例(7.5％);B组PR 30例(71.4％),NC 9例(21.4％),PD 3例(7.1％)。两组相比B组疗效明显优于A组(P<0.05),毒副作用B组明显低于A组(P<0.05)。结论 经皮左锁骨下药盒肝动脉灌注拓僖为主治疗晚期原发性肝癌副作用小,疗效高,值得进一步研究。

Objective To evaluate the efficacy of iniection of touxi(HCPT) through percutaneous left sub-clavian artery port-catheter system implantation ( PSPI) for treatment of advanced primary hepatic carcinoma. Methods A total of 82 cases of advanced primary hepatic carcinoma were divided into 2 groups: (1) Group A: 40 patients were treated once a month with transcatheter arterial embolization (TAE); (2)Group B:42 patients were treated by injection of touxi(HCPT) through percutaneous left subclavian artery port-catheter system implntation (PSPI). Result The response rate (CR+PR) was 47.5% and 71.4% in group A and group B(P<0.05), respectively. Conclusion Injection of touxi( HCPT) through percutaneous left subclavian artery port-catheter system implantation (PSPI) is an effective therapy for advanced primary hepatic carcinoma.